Seattle Genetics, Inc.
21823 - 30th Drive S.E.
Bothell
Washington
98021
U.S.A.
Phone:
425-527-4000
Fax:
425-527-4001
|
Committed to improving patient outcomes
At Seattle Genetics, we are committed to developing innovative antibody-based therapies that improve clinical outcomes for patients with cancer and autoimmune diseases. We are dedicated to addressing unmet medical need, and strive to achieve that goal through an unwavering commitment to excellence in clinical development.
Focusing on Clinical Development
Seattle Genetics is a clinical stage biotechnology company advancing a broad product pipeline of antibody-based therapies. Our lead program, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the FDA for patients with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is empowered by Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. In addition, we are conducting clinical trials with four other product candidates, lintuzumab (SGN-33), dacetuzumab (SGN-40) and SGN-75, for the treatment of cancer, and SGN-70, for autoimmune diseases. We are also advancing a pipeline of promising preclinical candidates and have robust research and development capabilities that are our engine for innovation and long-term growth.
Our proprietary ADC technology empowers antibodies by stably linking them to cell-killing drug payloads. The drug payload is inactive until released from the antibody inside the targeted cancer cell, thereby sparing normal tissue the toxicity of traditional chemotherapy. In addition to brentuximab vedotin, SGN-75 is an ADC that is in a phase I clinical trial and we are developing several preclinical ADC product candidates, including ASG-5ME, which is advancing towards a planned 2010 clinical trial for solid tumors.
Expanding Our Opportunities Through Collaboration
Collaborating with leading biopharmaceutical companies is a cornerstone of Seattle Genetics' business strategy. Product-focused collaborations, such as our exclusive worldwide collaboration agreement with Genentech (a wholly owned member of the Roche Group) to develop and commercialize dacetuzumab, provide significant near- and mid-term funding while bringing in additional resources and expertise to support, advance and expand promising development programs. Collaboration and license agreements around our proprietary ADC technology also generate cash for the company - more than $75 million to date - while providing further clinical validation of the ADC platform and, in some cases, opening the door to new product development opportunities.
Email:
contact@seagen.com
Ownership:
Web Site:
Seattle Genetics, Inc.
Employees:
Symbol: SGEN
|
|
|
Company News |
Seattle Genetics, Inc. (SGEN) and Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma
2/3/2010 10:14:32 AM
More...
|
Seattle Genetics, Inc. (SGEN) to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2009 Financial Results on February 9, 2010
2/2/2010 10:26:06 AM
More...
|
Seattle Genetics, Inc. (SGEN) to Present at the J.P. Morgan Healthcare Conference
1/5/2010 9:17:57 AM
More...
|
Seattle Genetics, Inc. (SGEN) (JOBS) in Licensing Deal with GlaxoSmithKline (GSK) (JOBS); Seattle to Get $12 Million Upfront; up to $390 Million in Milestone Payments
12/21/2009 6:36:11 AM
More...
|
Seattle Genetics, Inc. (SGEN) to Host Conference Call on December 15, 2009, to Discuss Brentuximab Vedotin (SGN-35) Partnering
12/15/2009 9:16:47 AM
More...
|
Millennium: The Takeda Oncology Company (JOBS) in $365M Deal for Seattle Genetics, Inc. (SGEN)'s (JOBS) Cancer Antibody
12/15/2009 6:54:15 AM
More...
|
Seattle Genetics, Inc. (SGEN) (JOBS) Announces Termination of Collaboration Agreement with Genentech (South SF) (RHHBY) (JOBS) for Dacetuzumab (SGN-40)
12/11/2009 7:11:07 AM
More...
|
Seattle Genetics, Inc. (SGEN) to Present at 2009 Deutsche Bank (DB) Biotech Confab
12/10/2009 8:46:45 AM
More...
|
Seattle Genetics, Inc. (SGEN) Reports Data from Dacetuzumab Phase Ib Combination Clinical Trials
12/8/2009 9:52:27 AM
More...
|
Seattle Genetics, Inc. (SGEN) Reports Positive Data from Phase I Weekly-Dosing Clinical Trial of Brentuximab Vedotin (SGN-35) in Lymphoma
12/7/2009 9:49:06 AM
More...
|
|
|
|